GlassScriptPhysician profile
Paul S Berger
NPI 1952308538
$2,609.18
in general payments reported to CMS, 2019-2025
23 companies · $196 in 2025
The $196 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $507 · 2020: $159 · 2021: $401 · 2022: $489 · 2023: $491 · 2024: $366 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,039 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,038.69 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $374.89 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $331.41 | 2019-2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $315.74 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $226.86 | 2019-2025 | Gardasil 9, Dificid, Capvaxive |
| Novo Nordisk INC | $207.52 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $175.95 | 2020-2024 | Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $157.36 | 2019-2025 | Airsupra, Farxiga |
| Amarin Pharma, INC. | $143.58 | 2019-2022 | |
| Sanofi Pasteur INC. | $137.34 | 2019-2024 | |
| Paratek Pharmaceuticals, INC. | $107.55 | 2022 | |
| Abbvie INC. | $94.08 | 2021-2024 | Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.60 | 2019-2024 | Ofev |
| Amgen INC. | $40.38 | 2021 | |
| Exact Sciences Corporation | $39.37 | 2023 | Cologuard Collection Kit |
| Incyte Corporation | $30.77 | 2022-2023 | Opzelura |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intra-Sana Laboratories | $30.39 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Astellas Pharma US INC | $29.12 | 2023 | Veozah |
| Bausch Health US, LLC | $27.44 | 2019 | |
| Glaxosmithkline, LLC. | $19.35 | 2024 | Shingrix, Arexvy |
| Althera Pharmaceuticals LLC | $16.93 | 2021 | |
| Medicure Pharma INC. | $14.42 | 2024 | Zypitamag |
| Eisai INC. | $13.68 | 2021 | |
| Seqirus USA INC | $11.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Berger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.